GenEdit Joins Forces with Genentech for Non-Viral Nanoparticle Development
Main Ideas:
- GenEdit has announced a collaboration with Genentech to develop non-viral, non-lipid, hydrophilic nanoparticles (HNPs) using its NanoGalaxy® platform.
- The NanoGalaxy platform consists of a library of thousands of unique nanoparticles created by combining hydrophilic polymers with small-molecule side chains.
Author’s Take:
GenEdit’s collaboration with Genentech to develop non-viral nanoparticles using the NanoGalaxy platform aims to address the delivery challenges in gene editing. The use of hydrophilic polymers and small-molecule side chains in creating targeted nanoparticles has the potential to revolutionize gene therapy. This collaboration showcases the importance of collaboration in advancing the field of biotechnology and genetic engineering.